ACTA2 and skin squamous cell carcinoma: To verify the pro‐tumorigenic effects of myCAFs, we first performed survival analyses using a dataset from The Cancer Genome Atlas (TCGA), which contained 252 patients with CSCC.[82] The GSVA score for myCAFs was calculated for each patient with CSCC using the marker gene set (ACTA2, POSTN, ITGB4, and FAP).